Insights · Report · Industry · May 3, 2026
eCOA, televisit telemetry, lab interfaces, and CDISC submission readiness when trials blend traditional sites with home-based participation.
Decentralized and hybrid trials generate data across electronic data capture, electronic clinical outcome assessments, wearables, home nursing visits, and central labs. Regulators still expect ALCOA plus attributes and traceable provenance.
The report maps interfaces, validation boundaries, and monitoring plans for each modality. A slick patient app without validated edit checks becomes a findings magnet.
Identity and linkage errors multiply when participants use personal devices. Master subject keys and device binding policies need explicit test evidence.
Privacy intersects GDPR, HIPAA contexts, and national trial rules simultaneously. Data localization for genomics subsets may require region-specific processing.
Vendor changes mid-trial require migration playbooks with parallel runs and statistical impact analysis. Do not hand-wave continuity.
Monitoring should blend central statistical monitoring with targeted source verification adapted to remote workflows. Cookie-cutter 100 percent SDV is neither feasible nor valued.
Submission readiness reviews should include trace matrices from protocol endpoints to analysis datasets. Late surprises delay filings more than cautious early alignment.
We provide tabletop prompts for cybersecurity incidents affecting ePRO devices and for integrity questions during social media recruitment spikes.
We can present findings in a working session, map recommendations to your portfolio and risk register, and help you prioritize next steps with clear owners and timelines.
